Aequus Pharmaceuticals Inc. announced that it has agreed to end its promotional service agreement with Sandoz Canada Inc. (Sandoz) on Tacrolimus Immediate Release (Immunosuppressant/Transplant) (Tacrolimus IR) and PrVistitan™ (bimatoprost 0.03% ophthalmic solution), effective December 31, 2022. The Sandoz commercial collaboration began nearly seven years ago and included both PrVistitan™ and Tacrolimus IR. Aequus deployed two dedicated national sales teams to accelerate the quick adoption of both products.

Through targeted awareness, valued added services, and customized support for both provincial and transplant centre stakeholders, Aequus has achieved a 4-Year CAGR of almost 20% for the Sandoz Tacrolimus IR brand. PrVistitan™ is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension. With an experienced ophthalmology sales force, targeted digital marketing services as well as strong relationships with Sandoz and the Canadian Ophthalmology community, Aequus achieved consistent growth in a competitive Canadian market.